7On July 1, the "time-honored" pharmaceutical company Taiantang announced that it received the "Notice of Filing of Cases from the China Securities Regulatory Commission" on June 30, 2022, because the company failed to disclose the 2021 annual report within the legal period. , According to the " Securities Law of the People's Republic of China ", " The Administrative Penalty Law of the People's Republic of China " and other laws and regulations, on June 13, 2022, the China Securities Regulatory Commission decided to file a case against the company.
Public information shows that Taiantang was founded in 1995 and has been fiercely engaged in business for more than 20 years. The company has developed into a national high-tech listed company that integrates pharmaceutical research and development, production and sales.
In April 2022, this was the time for the centralized disclosure of annual reports of listed companies, but Taiantang suddenly stated that “Affected by the epidemic, the company is difficult to complete the annual report-related work as originally planned, and objectively cannot disclose the audited 2021 annual report as scheduled as scheduled. ". Therefore, the company chose to postpone the disclosure of its annual report.
After a month and a half delay, Taiantang finally "handed in the papers" on the evening of June 15th. Financial data shows that the company's revenue in 2021 is 2.264 billion yuan, a year-on-year decrease of 36.79%, and the net profit attributable to the parent company is -803 million yuan, turning from profit to loss year-on-year. Regarding performance losses, the company said it was mainly due to the impairment of the company's goodwill and the losses caused by the divestment of 's heavy assets .
What is worth noting is that although Taiantang completed the annual report disclosure, the audit agency issued an audit report with qualified opinions on its 2021 financial statements. The audit agency said that Taiantang's subsidiary Guangdong Kangaiduo Digital Health Technology Co., Ltd. failed to implement effective inventory monitoring procedures for the inventory of 491 million yuan. (Article | "Financial World" Weekly Tang Guo)
